报价延迟最少15分钟:2026/05/14 14:13 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.29 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.20/--
|
|
企业价值
202.91M
|
| 资产负债 |
|
每股账面净值
7.47
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
539.57M
|
|
每股收益
7.66
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreementswith the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others. |
